In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel^®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

Starpharma today announced the appointment of an additional Vice President of Business Development with extensive pharmaceutical licensing experience.  Ms Eve Williamson, who will commence in the role with Starpharma in the New Year, has worked in the pharmaceutical industry for more than 20 years including senior roles in business development, marketing and sales, pricing and reimbursement, and clinical research.

Starpharma today announced the results of animal trials which show its dendrimer-enhanced version of docetaxel had significantly superior anti-cancer effects across a range of important cancer types when compared to Taxotere (docetaxel).